A prospective study of botulinum toxin for internal anal sphincter hypertonicity in children with Hirschsprung's disease

Robert K. Minkes, Jacob C. Langer

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Background: Internal anal sphincter hypertonicity with non-relaxation can cause persistent constipation and obstructive symptoms in children after surgery for Hirschsprung's disease. Intractable symptoms traditionally have been treated with anal myectomy, which may be ineffective or complicated by long-term incontinence. The authors evaluated prospectively the use of intrasphincteric botulinum toxin for these patients. Methods: Eighteen children were studied (age 1 to 13; median, 4 years). Botulinum toxin was injected (total dose 15 to 60 U) into 4 quadrants of the sphincter. Resting sphincter pressure was measured in 14 patients before and after injection. Ten have had 1 to 5 additional injections (total dose, 30 to 60 U per injection). Results: Four patients had no improvement in bowel function, 2 had improvement for less than 1 month, 7 had improvement for 1 to 6 months, and 5 had improvement more than 6 months. Nine of those with symptomatic improvement longer than 1 month had pressures measured, with a documented decrease in 8. Five with no significant clinical improvement had pressure measurements, with a decrease in 3. There were no adverse effects associated with botulinum toxin injection. Four children had new encopresis postinjection, which was mild and resolved in each case. Conclusions: Intrasphincteric botulinum toxin is a safe and less-invasive alternative to myectomy for symptomatic internal Sphincter hypertonicity. Persistent symptoms, despite a fall in sphincter pressure, suggest a nonsphincteric etiology. Repeat injections often are necessary for recurrent symptoms. Copyright (C) 2000 by W.B. Saunders Company.

Original languageEnglish (US)
Pages (from-to)1733-1736
Number of pages4
JournalJournal of Pediatric Surgery
Volume35
Issue number12
DOIs
StatePublished - 2000

Fingerprint

Hirschsprung Disease
Botulinum Toxins
Anal Canal
Prospective Studies
Injections
Pressure
Encopresis
Constipation

Keywords

  • Botulinum toxin
  • Hirschsprung's disease
  • Intestinal neuronal dysplasia

ASJC Scopus subject areas

  • Surgery

Cite this

A prospective study of botulinum toxin for internal anal sphincter hypertonicity in children with Hirschsprung's disease. / Minkes, Robert K.; Langer, Jacob C.

In: Journal of Pediatric Surgery, Vol. 35, No. 12, 2000, p. 1733-1736.

Research output: Contribution to journalArticle

@article{f9e3f389245643fab14c0722becdb6da,
title = "A prospective study of botulinum toxin for internal anal sphincter hypertonicity in children with Hirschsprung's disease",
abstract = "Background: Internal anal sphincter hypertonicity with non-relaxation can cause persistent constipation and obstructive symptoms in children after surgery for Hirschsprung's disease. Intractable symptoms traditionally have been treated with anal myectomy, which may be ineffective or complicated by long-term incontinence. The authors evaluated prospectively the use of intrasphincteric botulinum toxin for these patients. Methods: Eighteen children were studied (age 1 to 13; median, 4 years). Botulinum toxin was injected (total dose 15 to 60 U) into 4 quadrants of the sphincter. Resting sphincter pressure was measured in 14 patients before and after injection. Ten have had 1 to 5 additional injections (total dose, 30 to 60 U per injection). Results: Four patients had no improvement in bowel function, 2 had improvement for less than 1 month, 7 had improvement for 1 to 6 months, and 5 had improvement more than 6 months. Nine of those with symptomatic improvement longer than 1 month had pressures measured, with a documented decrease in 8. Five with no significant clinical improvement had pressure measurements, with a decrease in 3. There were no adverse effects associated with botulinum toxin injection. Four children had new encopresis postinjection, which was mild and resolved in each case. Conclusions: Intrasphincteric botulinum toxin is a safe and less-invasive alternative to myectomy for symptomatic internal Sphincter hypertonicity. Persistent symptoms, despite a fall in sphincter pressure, suggest a nonsphincteric etiology. Repeat injections often are necessary for recurrent symptoms. Copyright (C) 2000 by W.B. Saunders Company.",
keywords = "Botulinum toxin, Hirschsprung's disease, Intestinal neuronal dysplasia",
author = "Minkes, {Robert K.} and Langer, {Jacob C.}",
year = "2000",
doi = "10.1053/jpsu.2000.19234",
language = "English (US)",
volume = "35",
pages = "1733--1736",
journal = "Journal of Pediatric Surgery",
issn = "0022-3468",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - A prospective study of botulinum toxin for internal anal sphincter hypertonicity in children with Hirschsprung's disease

AU - Minkes, Robert K.

AU - Langer, Jacob C.

PY - 2000

Y1 - 2000

N2 - Background: Internal anal sphincter hypertonicity with non-relaxation can cause persistent constipation and obstructive symptoms in children after surgery for Hirschsprung's disease. Intractable symptoms traditionally have been treated with anal myectomy, which may be ineffective or complicated by long-term incontinence. The authors evaluated prospectively the use of intrasphincteric botulinum toxin for these patients. Methods: Eighteen children were studied (age 1 to 13; median, 4 years). Botulinum toxin was injected (total dose 15 to 60 U) into 4 quadrants of the sphincter. Resting sphincter pressure was measured in 14 patients before and after injection. Ten have had 1 to 5 additional injections (total dose, 30 to 60 U per injection). Results: Four patients had no improvement in bowel function, 2 had improvement for less than 1 month, 7 had improvement for 1 to 6 months, and 5 had improvement more than 6 months. Nine of those with symptomatic improvement longer than 1 month had pressures measured, with a documented decrease in 8. Five with no significant clinical improvement had pressure measurements, with a decrease in 3. There were no adverse effects associated with botulinum toxin injection. Four children had new encopresis postinjection, which was mild and resolved in each case. Conclusions: Intrasphincteric botulinum toxin is a safe and less-invasive alternative to myectomy for symptomatic internal Sphincter hypertonicity. Persistent symptoms, despite a fall in sphincter pressure, suggest a nonsphincteric etiology. Repeat injections often are necessary for recurrent symptoms. Copyright (C) 2000 by W.B. Saunders Company.

AB - Background: Internal anal sphincter hypertonicity with non-relaxation can cause persistent constipation and obstructive symptoms in children after surgery for Hirschsprung's disease. Intractable symptoms traditionally have been treated with anal myectomy, which may be ineffective or complicated by long-term incontinence. The authors evaluated prospectively the use of intrasphincteric botulinum toxin for these patients. Methods: Eighteen children were studied (age 1 to 13; median, 4 years). Botulinum toxin was injected (total dose 15 to 60 U) into 4 quadrants of the sphincter. Resting sphincter pressure was measured in 14 patients before and after injection. Ten have had 1 to 5 additional injections (total dose, 30 to 60 U per injection). Results: Four patients had no improvement in bowel function, 2 had improvement for less than 1 month, 7 had improvement for 1 to 6 months, and 5 had improvement more than 6 months. Nine of those with symptomatic improvement longer than 1 month had pressures measured, with a documented decrease in 8. Five with no significant clinical improvement had pressure measurements, with a decrease in 3. There were no adverse effects associated with botulinum toxin injection. Four children had new encopresis postinjection, which was mild and resolved in each case. Conclusions: Intrasphincteric botulinum toxin is a safe and less-invasive alternative to myectomy for symptomatic internal Sphincter hypertonicity. Persistent symptoms, despite a fall in sphincter pressure, suggest a nonsphincteric etiology. Repeat injections often are necessary for recurrent symptoms. Copyright (C) 2000 by W.B. Saunders Company.

KW - Botulinum toxin

KW - Hirschsprung's disease

KW - Intestinal neuronal dysplasia

UR - http://www.scopus.com/inward/record.url?scp=0033662849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033662849&partnerID=8YFLogxK

U2 - 10.1053/jpsu.2000.19234

DO - 10.1053/jpsu.2000.19234

M3 - Article

C2 - 11101725

AN - SCOPUS:0033662849

VL - 35

SP - 1733

EP - 1736

JO - Journal of Pediatric Surgery

JF - Journal of Pediatric Surgery

SN - 0022-3468

IS - 12

ER -